Skip Navigation LinksHome > January 2013 - Volume 35 - Issue 1 > Persistent Complete Response After Single-agent Sunitinib Tr...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e318266bf34
Online Articles: Clinical and Laboratory Observations

Persistent Complete Response After Single-agent Sunitinib Treatment in a Case of TFE Translocation Positive Relapsed Metastatic Pediatric Renal Cell Carcinoma

Chowdhury, Tanzina MD, PhD*; Prichard-Jones, Kathryn MD, PhD*,†; Sebire, Neil J. MD; Bier, Nelly BSc; Cherian, Abraham MD§; Sullivan, Maureen O. MD; O’Meara, Anne MD; Anderson, John MD, PhD*,†

Collapse Box

Abstract

Forty percent of renal cell carcinomas (RCCs) in childhood are characterized by translocation involving transcription factor E3 (TFE3) family members. Here, we describe a case of TFE3-positive RCC in which metastatic relapse to the mediastinal lymph nodes and pulmonary nodules was treated with single-agent sunitinib, a multitargeted tyrosine inhibitor. Complete radiologic remission was achieved after only 3 courses of treatment, and surgical exploration of metastases failed to identify any residual viable disease. The published experience of sunitinib in TFE-RCC is limited, and prospective evaluation of its activity in a larger number of patients is warranted.

© 2013 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.